Neutral
●
PRNewsWire
●
vor 6 Monaten
Theravance Biopharma Reaffirmed Financial Guidance Repeatedly Without Disclosing the Material Risk That Its Pivotal Trial Could Fail NEW YORK, March 18, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% when shares collapsed on March 3, 2026. In the quarters leading up to that drop, management reaffirmed financial guidance -- including $75 million in n...